Chemically targeting the PI3K family
- 20 March 2007
- journal article
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 35 (2) , 245-249
- https://doi.org/10.1042/bst0350245
Abstract
PI3K (phosphoinositide 3-kinase) is a key regulator of cell growth, metabolism and survival. The frequent activation of the PI3K pathway in cancer has stimulated widespread interest in identifying potent and selective inhibitors of PI3K isoforms. The present paper highlights recent progress in identifying such molecules and the challenges that remain for efforts to pharmacologically target the PI3K family.Keywords
This publication has 29 references indexed in Scilit:
- Furan-2-ylmethylene Thiazolidinediones as Novel, Potent, and Selective Inhibitors of Phosphoinositide 3-Kinase γJournal of Medicinal Chemistry, 2006
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin SignalingCell, 2006
- Mutation of the PIK3CA oncogene in human cancersBritish Journal of Cancer, 2006
- Discovery of Potent Chromen-4-one Inhibitors of the DNA-Dependent Protein Kinase (DNA-PK) Using a Small-Molecule Library ApproachJournal of Medicinal Chemistry, 2005
- Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone librariesBioorganic & Medicinal Chemistry Letters, 2004
- Gene Targeting: Attention to DetailCell, 2004
- High Frequency of Mutations of the PIK3CA Gene in Human CancersScience, 2004
- Structural Determinants of Phosphoinositide 3-Kinase Inhibition by Wortmannin, LY294002, Quercetin, Myricetin, and StaurosporineMolecular Cell, 2000
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- Phosphatidylinositol-3-OH kinase direct target of RasNature, 1994